ArticleJournal of virology2009
Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells.
Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- CD56Journal of leukocyte biology · 2017Article
- Host-virus interactions in hepatitis B and hepatitis C infection.Journal of gastroenterology · 2016Review
- Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients.Clinical and experimental immunology · 2015Article
- HCV J6/JFH1 tilts the capability of myeloid-derived dendritic cells to favor the induction of immunosuppression and Th17-related inflammatory cytokines.Pharmaceutical research · 2015Article
- Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection.The Journal of infectious diseases · 2014Article
- CD81 and hepatitis C virus (HCV) infection.Viruses · 2014Review
- Emerging concepts in immunity to hepatitis C virus infection.The Journal of clinical investigation · 2013Review
- Natural killer cells: multifaceted players with key roles in hepatitis C immunity.Immunological reviews · 2013Review
- Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?Virology : research and treatment · 2013Review
- Slc15a4, a gene required for pDC sensing of TLR ligands, is required to control persistent viral infection.PLoS pathogens · 2012Article
- Review
- Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline.The Journal of infectious diseases · 2012Article
- Dendritic cells in hepatitis C infection: can they (help) win the battle?Journal of gastroenterology · 2011Review
- Hepatitis C virus modulates human monocyte-derived dendritic cells.Journal of viral hepatitis · 2010Article
- Innate immunity against HIV: a priority target for HIV prevention research.Retrovirology · 2010Review
- Replication-independent activation of human plasmacytoid dendritic cells by the paramyxovirus SV5 Requires TLR7 and autophagy pathways.Virology · 2010Article
- Distinct intracellular trafficking of hepatitis C virus in myeloid and plasmacytoid dendritic cells.Journal of virology · 2010Article
- A look behind closed doors: interaction of persistent viruses with dendritic cells.Nature reviews. Microbiology · 2010Review
- The role of CD40 and CD154/CD40L in dendritic cells.Seminars in immunology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dendritic cells (DCs) are reported to be functionally deficient during chronic hepatitis C virus (HCV) infection. Differing results have been reported on direct effects of intact replicative-form HCV on DC function. To better understand the effect of HCV on DC function, we treated freshly purified human myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) with HCV JFH1. We found that HCV upregulated mDC maturation marker (CD83, CD86, and CD40) expression and did not inhibit Toll-like receptor 3 (TLR3) ligand [poly(I:C)]-induced mDC maturation, a finding consistent with the phenotype of DCs from HCV-infected subjects. At the same time, HCV JFH1 inhibited the ability of poly(I:C)-treated mDCs to activate naive CD4 T cells. In contrast, although there was no direct effect of virus on pDC maturation, HCV JFH1 inhibited TLR7 ligand (R848)-induced pDC CD40 expression, and this was associated with impaired ability to activate naive CD4 T cells. Parallel experiments with recombinant HCV proteins indicated HCV core protein may be responsible for a portion of the activity. Furthermore, HCV-mediated mDC maturation was dependent upon CD81-E2 interaction and, in part, TLR2. Using UV-treated HCV, we show that HCV-mediated mDC and pDC maturation is virus replication independent and, using strand specific PCR, we found no evidence for HCV replication within DCs. Because these effects of HCV on DC subset maturation and function in part recapitulate direct ex vivo analysis of DCs in chronic HCV infection, the mechanisms described here likely account for a portion of the DC subset defects observed in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.